Effects of Modified Qing’e Pill (加味青娥丸) on expression of adiponectin, bone morphogenetic protein 2 and coagulation-related factors in patients with nontraumatic osteonecrosis of femoral head

Cheng-gang Li; Lin Shen; Yan-Ping Yang; Xiao-Juan Xu; Bo Shuai; Chen Ma

doi:10.1007/s11655-016-2407-3

Your Location：

Home >

Browse articles >

Effects of Modified Qing’e Pill (加味青娥丸) on expression of adiponectin, bone morphogenetic protein 2 and coagulation-related factors in patients with nontraumatic osteonecrosis of femoral head

OriginalPaper | Updated：2021-08-27

- Effects of Modified Qing’e Pill (加味青娥丸) on expression of adiponectin, bone morphogenetic protein 2 and coagulation-related factors in patients with nontraumatic osteonecrosis of femoral head
- Effects of Modified Qing’e Pill (加味青娥丸) on expression of adiponectin, bone morphogenetic protein 2 and coagulation-related factors in patients with nontraumatic osteonecrosis of femoral head
- 中国结合医学杂志（英文版） 2017年23卷第3期页码：183-189
- Affiliations：
  
  Department of Integrated Traditional Chinese Medicine and Western Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology,Wuhan,China
- Author bio：
- Funds：
  
  Supported by the National Natural Science Foundation of China (No. 81273907)
- DOI：10.1007/s11655-016-2407-3
  中图分类号：
- 纸质出版日期：2017，
  
  网络出版日期：2016-5-6，
Scan for full text
Li, Cg., Shen, L., Yang, YP. et al. Effects of Modified Qing’e Pill (加味青娥丸) on expression of adiponectin, bone morphogenetic protein 2 and coagulation-related factors in patients with nontraumatic osteonecrosis of femoral head., Chin. J. Integr. Med. 23, 183–189 (2017). https://doi.org/10.1007/s11655-016-2407-3

Cheng-gang Li, Lin Shen, Yan-Ping Yang, et al. Effects of Modified Qing’e Pill (加味青娥丸) on expression of adiponectin, bone morphogenetic protein 2 and coagulation-related factors in patients with nontraumatic osteonecrosis of femoral head[J]. Chinese Journal of Integrative Medicine, 2017,23(3):183-189.
Li, Cg., Shen, L., Yang, YP. et al. Effects of Modified Qing’e Pill (加味青娥丸) on expression of adiponectin, bone morphogenetic protein 2 and coagulation-related factors in patients with nontraumatic osteonecrosis of femoral head., Chin. J. Integr. Med. 23, 183–189 (2017). https://doi.org/10.1007/s11655-016-2407-3 DOI：

Cheng-gang Li, Lin Shen, Yan-Ping Yang, et al. Effects of Modified Qing’e Pill (加味青娥丸) on expression of adiponectin, bone morphogenetic protein 2 and coagulation-related factors in patients with nontraumatic osteonecrosis of femoral head[J]. Chinese Journal of Integrative Medicine, 2017,23(3):183-189. DOI： 10.1007/s11655-016-2407-3.

摘要

To observe the regulation of Chinese herbal medicine

Modifified Qing’e Pill (加味青娥丸

MQEP)

on the expression of adiponectin

bone morphogenetic protein 2 (BMP2)

osteoprotegerin (OPG) and other potentially relevant risk factors in patients with nontraumatic osteonecrosis of the femoral head (ONFH). A total of 96 patients with nontraumatic ONFH were unequal randomly divided into treatment group (60 cases) and control group (36 cases). The treatment group were treated with MQEP while the control group were treated with simulated pills. Both groups were given caltrate D. Six months were taken as a treatment course. Patients were followed up every 2 months. The levels of plasma adiponectin

BMP2

OPG

von Willebrand factor (vWF)

von Willebrand factor cleaving protease (vWF-cp)

plasminogen activator inhibitor 1 (PAI-1)

tissue plasminogen activator (tPA)

C-reactive protein (CRP)

blood rheology

bone mineral density (BMD) of the femoral head and Harris Hip Score were measured before and after treatment. After 6 months of treatment

compared with the control group

patients in the treatment group had signifificantly higher adiponectin and BMP2 levels (P<0.01 and P=0.013

respectively)

lower vWF

PAI-1 and CRP levels (P=0.019

P<0.01 and P<0.01

respectively)

and lower blood rheology parameters. BMD of the femoral neck

triangle area and Harris Hip Score in the treatment group were signifificantly higher than those in the control group. Moreover

plasma adiponectin showed a positive association with BMP2 (r=0.231

P=0.003) and a negative association with PAI-1 (r=–0.159

P<0.05). MQEP may play a protective role against nontraumatic ONFH by increasing the expression of adiponectin

regulating bone metabolism and improving the hypercoagulation state

which may provide an experimental base for its clinical effects.

Abstract

To observe the regulation of Chinese herbal medicine

Modifified Qing’e Pill (加味青娥丸

MQEP)

on the expression of adiponectin

bone morphogenetic protein 2 (BMP2)

BMP2

OPG

von Willebrand factor (vWF)

von Willebrand factor cleaving protease (vWF-cp)

plasminogen activator inhibitor 1 (PAI-1)

tissue plasminogen activator (tPA)

C-reactive protein (CRP)

blood rheology

bone mineral density (BMD) of the femoral head and Harris Hip Score were measured before and after treatment. After 6 months of treatment

compared with the control group

patients in the treatment group had signifificantly higher adiponectin and BMP2 levels (P<0.01 and P=0.013

respectively)

lower vWF

PAI-1 and CRP levels (P=0.019

P<0.01 and P<0.01

respectively)

and lower blood rheology parameters. BMD of the femoral neck

triangle area and Harris Hip Score in the treatment group were signifificantly higher than those in the control group. Moreover

plasma adiponectin showed a positive association with BMP2 (r=0.231

P=0.003) and a negative association with PAI-1 (r=–0.159

P<0.05). MQEP may play a protective role against nontraumatic ONFH by increasing the expression of adiponectin

regulating bone metabolism and improving the hypercoagulation state

which may provide an experimental base for its clinical effects.

关键词

osteonecrosisfemoral headChinese Herbal Medicineadiponectinbone morphogenetic protein 2plasminogen activator inhibitor 1

Keywords

osteonecrosisfemoral headChinese Herbal Medicineadiponectinbone morphogenetic protein 2plasminogen activator inhibitor 1

references

Mont MA, Jones LC, Hungerford DS. Nontraumatic osteonecrosis of the femoral head: ten years later. J Bone Joint Surg Am 2006;88: 1117–1132.

Tingart M, Beckmann J, Opolka A, Matsuura M, Wiech O, Grifka J, et al. Influence of factors regulating bone formation and remodeling on bone quality in osteonecrosis of the femoralhead. Calcif Tissue Int 2008;82: 300–308.

Kamiva N, Shafer S, Oxendine I, Mortlock DP, Chandler RL, Oxburgh L, et al. Acute BMP2 upregulation following induction of ischemic osteonecrosis in immature femoral head. Bone 2013;53: 239–247.

ARCO. Committee on terminology and classification. ARCO News 1992;4: 41–46.

Nozaki Y, Kumagai K, Miyata N, Niwa M. Pravastatin reduces steroid-induced osteonecrosis of the femoral head in SHRSP rats. Acta Orthop 2012;83: 87–92.

Lykissas MG, Gelalis ID, Kostas-Agnantis IP, Vozonelos G, Korompilias AV. The role of hypercoagulability in the development of osteonecrosis of the femoral head. Orthop Rev (Pavia) 2012;4: 73–78.

Miyanishi K, Yamamoto T, Irisa T, Yamashita A, Jingushi S, Noguchi Y, et al. Bone marrow fat cell enlargement and a rise in intraosseous pressure in steroid-treated rabbits with osteonecrosis. Bone 2002;30: 185–190.

Calder JD, Buttery L, Revell PA, Pearse M, Polak JM. Apoptosis—a significant cause of bone cell death in osteonecrosis of the femoral head. J Bone Joint Surg Br 2004;86: 1209–1213

Youm YS, Lee SY, Lee SH. Apoptosis in the osteonecrosis of the femoral head. Clin Orthop Surg 2010;2: 250–255.

Assouline-Dayan Y, Chang C, Greenspan A, Shoenfeld Y, Gershwin ME. Pathogenesis and natural history of osteonecrosis. Semin Arthrit Rheum 2002;32: 94–124.

Kadowaki T, Yamauchi T, Kubota N, Hara K, Ueki K, Tobe K. Adiponectin and adiponectin receptors in insulin resistance, diabetes, and the metabolic syndrome. J Clin Invest 2006;116: 1784–1792.

Tamang HK, Timilsina U, Singh KP, Shrestha S, Pandey B, Basnet S, et al. Assessment of adiponectin level in obese and lean Nepalese population and its possible correlation with lipidprofile: a cross-sectional study. Indian J Endocrinol Metab 2013;17: 349–354.

Williams GA, Wang Y, Callon KE, Watson M, Lin JM, Lam JB, et al. In vitro and in vivo effects of adiponectin on bone. Endocrinology 2009;150: 3603–3610.

Berner HS, Lyngstadaas SP, Spahr A, Monjo M, Thommesen L, Drevon CA, et al. Adipo-nectin and its receptors are expressed in bone-forming cells. Bone 2004;35: 842–849.

Shinoda Y, Yamaguchi M, Ogata N, Akune T, Kubota N, Yamauchi T, et al. Regulation of bone formation by adiponectin through autocrine/paracrine and endocrine pathways. J Cell Biochem 2006;99: 196–208.

Lee HW, Kim SY, Kim AY, Lee EJ, Choi JY, Kim JB. Adiponectin stimulates osteoblast differentiation through induction of COX2 in mesenchymal progenitor cells. Stem Cells 2009;27: 2254–2262.

Luo XH, Guo LJ, Yuan LQ, Xie H, Zhou HD, Wu XP, et al. Adiponectin stimulates human osteoblasts proliferation and differentiation via the MAPK signaling pathway. Exp Cell Res 2005;309: 99–109.

Oshima K, Nampei A, Matsuda M, Iwaki M, Fukuhara A, Hashimoto J, et al. Adipo-nectin increases bone mass by suppressing osteoclast and activating osteoblast. Biochem Biophys Res Commun 2005;331: 520–526.

Shehzad A, Iqbal W, Shehzad O, Lee YS. Adiponectin: regulation of its production and its role in human diseases. Hormones (Athens) 2012;11: 8–20.

Ehling A, Schäffler A, Herfarth H, Tarner IH, Anders S, Distler O, et al. The potential of adiponectin in driving arthritis. J Immunol 2006;176: 4468–4478.

Mather KJ, Goldberg RB. clinical use of adiponectin as a marker of metabolic dysregulation. Best Pract Res Clin Endocrinol Metab 2014;28: 107–117.

Shuai B, Shen L, Yang YP, Xie J, Shou ZX, Wei B. Low plasma adiponectin as a potential biomarker for osteonecrosis of the femoral head. J Rheumatol 2010;37: 2151–2155.

Huang CY, Lee CY, Chen MY, Tsai HC, Hsu HC, Tang CH. Adiponectin increases BMP-2 expression in osteoblasts via AdipoR receptor signaling pathway. J Cell Physiol 2010;224: 475–483.

Kamiya N, Shafer S, Oxendine I, Mortlock DP, Chandler RL, Oxburgh L, et al. Acute BMP2 upregulation following induction of ischemic osteonecrosis in immature femoral head. Bone 2013;53: 239–247.

Malizos KN, Karantanas AH, Varitimidis SE, Dailiana ZH, Bargiotas K, Maris T. Osteo necrosis of the femoral head: etiology, imaging and treatment. Eur J Radiol 2007;63: 16–28.

Molino D, de Santo NG, Marotta R, Anastasio P, Mosavat M, de Lucia D. Plasma levels of plasminogen activator inhibitor type 1, factor I, prothrombin activation fragment 1+2, anticardiolipin, and antiprothrombin antibodies are risk factors for thrombosis in hemodialysis patients. Semin Nephrol 2004;24: 495–501.

Zalavras C, Dailiana Z, Elisaf M, Bairaktari E, Vlachogiannopoulos P, Katsaraki A, et al. Potential aetiological factors concerning the development of osteonecrosis of the femoral head. Eur J Clin Invest 2000;30: 215–221.

Chauhan AK, Motto DG, Lamb CB, Bergmeier W, Dockal M, Plaimauer B, et al. Systemic antithrombotic effects of ADAMTS13. J Exp Med 2006;203: 767–776.

Jansson JH, Nilsson TK, Johnson O. von Willebrand factor in plasma: a novel risk factor for recurrent myocardial infarction and death. Br Heart J 1991;66: 351–355.

Jansson JH, Johansson B, Boman K, Nilsson TK. Hypofibrinolysis in patients with hyper-tension and elevated cholesterol. J Intern Med 1991;229: 309–316.

Li JH, Wu YL, Ye JH, Ning YG, Yu HY, Peng ZJ, et al. Effects of blood-activating and stasis-removing drugs combined with VEGF gene transfer on angiogenesis inischemic necrosis of the femoral head. J Tradit Chin Med 2009;29: 216–219.

FULL TEXT LINK

More>

浏览量

Downloads

CSCD

文章被引用时，请邮件提醒。

Submit

工具集

关联资源

Development is a high level inheritance for China Time-honored Brand products

Effect of Chinese herbal medicine for nourishing yin, supplementing qi, and activating blood on the Th1/Th2 immune balance in peripheral blood in patients with primary Sjogren’s syndrome

Chinese herbal medicine in the treatment of nonalcoholic fatty liver disease

Therapeutic effect of Chinese herbal medicine for strengthening qi, nourishing yin, and removing stasis on serum osteopontin and quality of life of patients with primary Sjogren's syndrome

Effects and mechanisms of actions of Chinese herbal medicines for asthma